Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide

Hypertension

Volumn 29, Issue 1 II, 1997, Pages 394-400

  Li, Ping ^a   Chappell, Mark C ^a   Ferrario, Carlos M ^a   Brosnihan, K Bridget ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin peptides; angiotensin converting enzyme; coronary artery; dog; endothelium derived relaxing factors; kinins; nitric oxide

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN II [1 SARCOSINE 8 THREONINE]; ANGIOTENSIN II [1-7]AMIDE[1 SARCOSINE]; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIUM DERIVED RELAXING FACTOR; ICATIBANT; INDOMETACIN; LISINOPRIL; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY; DOG; DRUG COMPETITION; DRUG POTENTIATION; ENZYME INHIBITION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOLATED ARTERY; NONHUMAN; PRIORITY JOURNAL; VASODILATATION;

EID: 0031034312     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.29.1.394     Document Type: Article

References (46)

1. Ferrario CM, Brosnihan KB, Diz DI, Jaiswal N, Khosla MC, Milsted A, Tallant EA. Angiotensin-(1-7): a new hormone of the angiotensin system. Hypertension. 1991;18(suppl III):126-133.
2. Ferrario CM. Biological roles of angiotensin-(1-7). Hypertens Res. 1992;15:61-66.
3. Fitzsimons JT. The effect on drinking of peptide precursors and of shorter chain peptide fragments of angiotensin II injected into the rat's diencephalon. J Physiol. 1971;214:295-303.
4. Peach MJ, Chiu BA. Stimulation and inhibition of aldosterone biosynthesis in vitro by angiotensin II and analogs. Circ Res. 1974; 34/35:I-7-I-13.
5. Schiavone MT, Santos RAS, Brosnihan KB, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A. 1988;85:4095-4098.
6. Jaiswal N, Diz DI, Tallant EA, Khosla MC, Ferrario CM. Characterization of angiotensin receptors mediating prostaglandin synthesis in C6 glioma cells. Am J Physiol. 1991;260:R1000-R1006.
7. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
8. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523-528.
9. Porsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol. 1994;111:652-654.
10. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension. 1996;28:104-108.
11. Moriguchi A, Tallant EA, Matsumura K, Reilly TM, Walton H, Ganten D, Ferrario CM. Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension. 1995;25:1260-1265.
12. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol. 1995;269:H313-H319.
13. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin-(1-7). Peptides. 1993;14:679-684.
14. Meng W, Busija DW. Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles. Stroke. 1993;24:2041-2045.
15. Heyne N, Beer W, Muhlbauer B, Osswald H. Renal response to angiotensin (1-7) in anesthetized rats. Kidney Int. 1995;47:975-976.
16. Paula RD, Lima CV, Khosla MC, Santos RAS. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension. 1995;26:1154-1159.
17. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
18. Holtz J, Goetz RM. The endothelium and the renin-angiotensin system. Arzneimittelforschung Drug Res. 1994;44:397-401.
19. Erdos EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension. 1990;16:363-370.
20. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides. 1993;14:883-891.
21. Santos RAS, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension. 1992;19:II-56-II-61.
22. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994;23:439-449.
23. Bull HG, Thornberry NA, Cordes EH. Purification of angiotensin-converting enzyme from rabbit lung and human plasma by affinity chromatography. J Biol Chem. 1985;260:2963-2972.
24. Hooper NM, Turner AJ. Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin converting enzyme) from pig brain: a re-evaluation of their role in neuropeptide metabolism. Biochem J. 1987;241:625-633.
25. Chappell MC, Welches WR, Brosnihan KB, Ferrario CM. Inhibition of angiotensin converting enzyme by the metalloendopeptidase 3.4.24.15 inhibitor c-phenylpropyl-alanyl-alanyl-phenylalanyl-p-amino-benzoate. Peptides. 1992;13:943-946.
26. Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM. Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4.24.15) in vascular smooth muscle cells. J Vasc Med Biol. 1994;5:129-137.
27. Mizuno K, Niimura S, Tani M, Saito I, Sanada H, Takahashi M, Okazaki K, Yamaguchi M, Fukuchi S. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats. Life Sci. 1992;51:183-187.
28. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, Kadowitz PJ. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol. 1993; 234:35-42.
29. Dzau VJ. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res Cardiol. 1993;88:1-14.
30. Paul M, Bachmann J, Ganten D. The tissue renin-angiotensin systems in cardiovascular disease. Trends Cardiovasc Med. 1992;2:94-99.
31. Hilgers KF, Peters J, Veelken R, Sommer M, Rupprecht G, Ganten D, Luft FC, Mann JFE. Increased vascular angiotensin formation in female rats harboring the mouse Ren-2 gene. Hypertension. 1992; 19:687-691.
32. Mombouli JV, Vanhoutte PM. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol. 1992;20:S74-S83.
33. Vanhoutte PM, Boulanger CM, Illiano SC, Nagao T, Vidal M, Mombouli JV. Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol. 1993;22:S10-S16.
34. Nolly H, Carretero OA, Scicli AG. Kallikrein release by vascular tissue. Am J Physiol. 1993;265:H1209-H1214.
35. Graf K, Graf M, Bossaller C, Niehus J, Schulz K-D, Schwelk WA, Fleck E. Degradation of bradykinin by neutral endopeptidase (EC 3.4.24.11) in cultured human endothelial cells. Eur J Clin Chem Clin Biochem. 1993;31:267-272.
36. Weimer G, Scholkens BA, Linz W. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res. 1994;28:166-172.
37. Grafe M, Bossaller C, Graf K, Schwelk WA, Baumgarten CR, Hildebrandt A, Fleck E. Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am J Physiol. 1993;264:H1493-H1497.
38. Bossaller C, Auch-Schwelk W, Grafe M, Graf K, Baumgarten C, Fleck E. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelium-dependent vascular relaxation. Agents Actions Suppl. 1992;38:171-179.
39. Gohlke P, Bunning P, Bonner G, Unger T. ACE inhibitor effect on bradykinin metabolism in the vascular wall. Agents Actions Suppl. 1992;38:178-185.
40. Mombouli JV, Iliano S, Nagao T, Burden TS, Vanhoutte PM. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res. 1992;71:137-144.
41. Schwelk WA, Bossaller C, Claus M, Graf K, Grafe M, Fleck E. Local potentiation of bradykinin-induced vasodilation by converting-enzyme inhibition in isolated coronary arteries. J Cardiovasc Pharmacol. 1992;20:S62-S67.
42. Johnston CI, Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. London, England: Gower Medical Publishing; 1993:87.1-87.15.
43. Skidgel RA, Erdos EG, Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. New York, NY: Gower Medical Publishing; 1993:10.1-10.10.
44. Matsufuji H, Matsui T, Ohshige S, Kawasaki T, Osajima K, Osajima Y. Antihypertensive effects of angiotensin fragments in SHR. Biosci Biotech Biochem. 1995;59:1398-1401.
45. 8) bradykinin). Eur J Pharmacol. 1992;210:115-120.
46. Linz W, Scholkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992;20:S83-S90.